An exploration into the science, regulation, consequences, and future of drug quality in the U.S.
Quality deficiencies in the drug supply chain, sometimes resulting in large-scale drug recalls, have captured headlines in the US in recent years.
But are the quality issues featured in the media widespread, or are they unfortunate one-off events driven by bad actors in the system?
The 2021 Pharmaceutical Outcomes and Policy Seminar will examine the complex and interrelated scientific, regulatory, supply chain, and system factors that underpin drug supply and utilization in the US. Experts will explain the challenges they face in ensuring that patients have access to pharmaceutical products that are safe and effective and of high quality. Participants will consider the implications of potential erosion in generic drug utilization on patient outcomes and costs. Finally, industry leaders will pose regulatory, delivery, and commercial solutions to improve the quality of the drug supply chain.
Investigative journalist and NYT best-selling author of “Bottle of Lies”
Senior Science Advisor, Office of Research and Standards, Office of Generic Drugs
Senior Vice President for Sciences and Regulatory Affairs
Associate Professor, Department of Markets, Public Policy and Law, Questrom School of Business
Assistant Professor, College of Pharmacy
Senior Market Development Manager
Dean and Professor, Pharmacy
Clinical Professor, College of Pharmacy
2020 Seminar Weekend Highlights
The 2020 seminar took place on March 7-8 and focused on real-world evidence.